Literature DB >> 19070478

Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.

Paul Gutwein1, Anja Schramme, Nina Sinke, Mohamed Sadek Abdel-Bakky, Beren Voss, Nicholas Obermüller, Kai Doberstein, Michael Koziolek, Florian Fritzsche, Manfred Johannsen, Klaus Jung, Helmut Schaider, Peter Altevogt, Andreas Ludwig, Josef Pfeilschifter, Glen Kristiansen.   

Abstract

The aim of our study was to analyse the expression of CXCL16, ADAM10 and CXCR6 in renal cell carcinoma (RCC) tissue and to correlate the expression pattern with clinicopathologic data, including patient survival. Furthermore, we investigated CXCL16, ADAM10 and CXCR6 expressions by FACS, immunofluorescence and ELISA analysis in renal carcinoma cell lines. Our immunohistochemical analysis on tissue microarray of renal cancer samples of 104 patients revealed that ADAM10 correlated significantly with tumour stage, pathological nodal status, M status and lymphangiosis carcinomatosa. CXCL16, CXCR6 and ADAM10 were significantly increased in papillary carcinomas. Importantly, high levels of CXCL16 expression in renal cancer tissue correlated with better survival of patients, and CXCL16 correlated inversely to the tumour stage. In addition, inhibition of CXCL16 induced the migration of renal cancer cells assuming an anti-migratory function of transmembrane CXCL16. Taken together, our data demonstrate that downregulation of CXCL16 plays an important role in renal cancer development and progression, and that CXCL16 in RCC is an independent prognostic marker for better patient survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070478     DOI: 10.1016/j.ejca.2008.10.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  32 in total

1.  Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation.

Authors:  Satoko Matsumura; Sandra Demaria
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

Review 2.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

Review 3.  Natural killer cell memory.

Authors:  Silke Paust; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

4.  Human adipose tissue macrophages display activation of cancer-related pathways.

Authors:  Thérèse Hérvée Mayi; Mehdi Daoudi; Bruno Derudas; Barbara Gross; Gael Bories; Kristiaan Wouters; John Brozek; Robert Caiazzo; Violeta Raverdi; Marie Pigeyre; Paola Allavena; Alberto Mantovani; François Pattou; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  J Biol Chem       Date:  2012-04-17       Impact factor: 5.157

5.  Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer.

Authors:  Jun Taik Lee; Sang Don Lee; Jeong Zoo Lee; Moon Kee Chung; Hong Koo Ha
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

6.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

Review 7.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

8.  CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.

Authors:  Paul Gutwein; Mohamed Sadek Abdel-Bakky; Anja Schramme; Kai Doberstein; Nicole Kämpfer-Kolb; Kerstin Amann; Ingeborg A Hauser; Nicholas Obermüller; Christine Bartel; Abdel-Aziz H Abdel-Aziz; El Sayed M El Sayed; Josef Pfeilschifter
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

Review 9.  Regulation of chemokine expression in the tumor microenvironment.

Authors:  Anton V Gorbachev; Robert L Fairchild
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 10.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.